Healthcare >> Analyst Interviews >> March 20, 2020
Several Readouts on Allogeneic Cell Therapy Expected in 2020
Raju Prasad is an Analyst focused on therapeutics at William Blair & Company, L.L.C. He joined the firm in March 2014. Dr. Prasad previously worked as a research associate at the University of North Carolina’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. Dr. Prasad has a degree in cell biology and neuroscience from Rutgers University, an M.S. degree in exercise physiology from the University of Delaware and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus in genetic toxicology and mutagenesis. Profile
Word count: 2,806
TWST: What do you cover?
Dr. Prasad: I primarily focus on cell and gene therapy, and gene editing. I also cover some rare disease